• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    InfuSystem Announces Appointment of Carrie Lachance as President

    3/2/21 6:30:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care
    Get the next $INFU alert in real time by email

    ROCHESTER HILLS, Michigan, March 02, 2021 (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that Carrie Lachance has been appointed as President in addition to her current role as Chief Operating Officer.

    Richard DiIorio, chief executive officer of InfuSystem said, “I am pleased to announce the promotion of Carrie Lachance to President of InfuSystem. Carrie has achieved outstanding results exhibiting solid leadership in her role as Chief Operating Officer in managing patient and customer care, including biomedical, clinical, customer service, logistics and revenue cycle management. In the new expanded role as President, Carrie will continue to lead these efforts and work with me to lead the team on the implementation and execution of our growth strategy. I am confident that Carrie’s broad base of health care experience and knowledge is well suited to grow and scale up our two operating platforms – Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME) – with new therapies and products.” 

    Mr. DiIorio continued, “The appointment of Carrie as President continues my commitment to build a strong leadership team with deep industry knowledge and proven leadership experience. I am dedicated to our long-term goal of making InfuSystem a leading health care services company. With the recent key leadership additions of Barry Steele as Chief Financial Officer, Jeannine Lombardi Sheehan as Chief Administrative Officer and Tom Ruiz as Chief Commercial Officer, I believe the Company is well positioned to deliver the industry’s best patient care and customer service as we work to expand our portfolio with new therapies in the coming years.”

    Carrie Lachance joined InfuSystem in 2010 and serves as the Company’s Chief Operating Officer (“COO”). Prior to her appointment as COO, Carrie held numerous positions with the Company including management roles in Clinical Resources and Clinical Sales. Carrie brings extensive clinical knowledge from more than 20 years in the medical field. Her medical career began in 1996 as a Hospital Corpsman in the U.S. Navy and Naval Reserves. Her nursing knowledge and experience in both the hospital and clinic settings, as well as oncology medical sales and product development, have been instrumental in promoting positive relations with partners, vendors, and distributors. 

    Carrie is a Certified Infusion Nurse and a member of the Infusion Nurses Society. She earned a Bachelor of Science degree in Nursing from Rivier University and earned her Master’s in Business Administration from Rivier University. 

    About InfuSystem Holdings, Inc.

    InfuSystem Holdings, Inc. (NYSE American: INFU), is a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The lead platform is Integrated Therapy Services (“ITS”), providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The ITS segment is comprised of Oncology, Pain Management, and Wound Therapy businesses. The second platform, Durable Medical Equipment Services (“DME Services”), supports the ITS platform and leverages strong service orientation to win incremental business from its direct payor clients. The DME Services segment is comprised of direct payor rentals, pump and consumable sales, and biomedical services and repair.  Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada.

    Forward-Looking Statements

    Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, business plans, objectives and prospects, future operating or financial performance. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Forward-looking statements are subject to factors, risks and uncertainties that could cause actual results to differ materially, including, but not limited to, the uncertain impact of the COVID-19 pandemic, our dependence on estimates of collectible revenue, potential litigation, changes in third-party reimbursement processes, changes in law and other risk factors disclosed in the Company’s most recent annual report on Form 10-K and, to the extent applicable, quarterly reports on Form 10-Q. All forward-looking statements made in this press release speak only as of the date hereof. We do not undertake any obligation to update any forward-looking statements to reflect future events or circumstances, except as required by law.

    Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com.

    # # #

    CONTACT:
    Joe Dorame, Joe Diaz & Robert Blum
    Lytham Partners, LLC
    602-889-9700

    Get the next $INFU alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INFU

    DatePrice TargetRatingAnalyst
    7/22/2025$12.00Buy
    Roth Capital
    9/26/2024$13.00Buy
    B. Riley Securities
    More analyst ratings

    $INFU
    SEC Filings

    View All

    SEC Form 10-Q filed by InfuSystems Holdings Inc.

    10-Q - InfuSystem Holdings, Inc (0001337013) (Filer)

    8/5/25 5:17:03 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystems Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - InfuSystem Holdings, Inc (0001337013) (Filer)

    8/5/25 6:29:43 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystems Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - InfuSystem Holdings, Inc (0001337013) (Filer)

    7/29/25 4:28:01 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on InfuSystem with a new price target

    Roth Capital initiated coverage of InfuSystem with a rating of Buy and set a new price target of $12.00

    7/22/25 7:53:05 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on InfuSystem with a new price target

    B. Riley Securities initiated coverage of InfuSystem with a rating of Buy and set a new price target of $13.00

    9/26/24 7:35:18 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    Northland Capital initiated coverage on InfuSystem with a new price target

    Northland Capital initiated coverage of InfuSystem with a rating of Outperform and set a new price target of $27.00

    4/26/21 8:42:07 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eichenbaum Kenneth D. bought $10,360 worth of shares (2,000 units at $5.18), increasing direct ownership by 50% to 6,000 units (SEC Form 4)

    4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    5/28/25 4:24:49 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    Director Hundzinski Ronald T bought $30,450 worth of shares (5,000 units at $6.09) (SEC Form 4)

    4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    5/20/25 6:54:45 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    President and COO Lachance Carrie bought $18,987 worth of shares (3,132 units at $6.06), increasing direct ownership by 2% to 190,212 units (SEC Form 4)

    4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    5/19/25 7:58:16 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InfuSystem Reports Second Quarter 2025 Financial Results

    Record Net Revenues of $36.0 million Representing 7% Growth from the Prior Year Net income of $2.6 million, up 262% Adjusted EBITDA (non-GAAP) of $8.0 million, up 32% Adjusted EBITDA (non-GAAP) margin expanded by 4.3% to 22.3% Year-to-Date Net Operating Cash Flow of $8.8 million, up 227% Stock Repurchases totaled $3.5 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Overview: Net revenues totaled $36.0

    8/5/25 6:30:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem to Report Second Quarter 2025 Financial Results on August 5, 2025

    Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue second quarter 2025 financial results on Tuesday, August 5, 2025, before the market opens. The Company will also conduct a conference call for all interested parties on Tuesday, August 5, 2025 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the

    7/29/25 4:30:00 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem Reports First Quarter 2025 Financial Results

    Record Net Revenues of $34.7 million Representing 9% Growth from the Prior Year Net loss of $0.3 million Adjusted EBITDA (non-GAAP) of $6.3 million, up 64% Adjusted EBITDA (non-GAAP) margin expanded by 6.2% to 18.2% Stock Repurchases totaled approximately $3.0 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the first quarter ended March 31, 2025. 2025 First Quarter Overview: Net revenues totaled $34.7 million, an increase of 9% vs. prior year. Patient Services net rev

    5/8/25 6:30:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Shuda Scott disposed of 2,242 shares and sold $55,622 worth of shares (5,752 units at $9.67), decreasing direct ownership by 8% to 94,000 units (SEC Form 4)

    4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    8/22/25 5:33:54 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    New insider Sviokla John J claimed ownership of 10,000 shares (SEC Form 3)

    3 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    6/16/25 7:38:02 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    Director Eichenbaum Kenneth D. bought $10,360 worth of shares (2,000 units at $5.18), increasing direct ownership by 50% to 6,000 units (SEC Form 4)

    4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    5/28/25 4:24:49 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by InfuSystems Holdings Inc.

    SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)

    12/9/24 6:38:13 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by InfuSystems Holdings Inc.

    SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)

    12/6/24 5:07:04 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by InfuSystems Holdings Inc.

    SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)

    9/24/24 2:06:02 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Financials

    Live finance-specific insights

    View All

    InfuSystem Reports Second Quarter 2025 Financial Results

    Record Net Revenues of $36.0 million Representing 7% Growth from the Prior Year Net income of $2.6 million, up 262% Adjusted EBITDA (non-GAAP) of $8.0 million, up 32% Adjusted EBITDA (non-GAAP) margin expanded by 4.3% to 22.3% Year-to-Date Net Operating Cash Flow of $8.8 million, up 227% Stock Repurchases totaled $3.5 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Overview: Net revenues totaled $36.0

    8/5/25 6:30:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem to Report Second Quarter 2025 Financial Results on August 5, 2025

    Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue second quarter 2025 financial results on Tuesday, August 5, 2025, before the market opens. The Company will also conduct a conference call for all interested parties on Tuesday, August 5, 2025 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the

    7/29/25 4:30:00 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem Reports First Quarter 2025 Financial Results

    Record Net Revenues of $34.7 million Representing 9% Growth from the Prior Year Net loss of $0.3 million Adjusted EBITDA (non-GAAP) of $6.3 million, up 64% Adjusted EBITDA (non-GAAP) margin expanded by 6.2% to 18.2% Stock Repurchases totaled approximately $3.0 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the first quarter ended March 31, 2025. 2025 First Quarter Overview: Net revenues totaled $34.7 million, an increase of 9% vs. prior year. Patient Services net rev

    5/8/25 6:30:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Leadership Updates

    Live Leadership Updates

    View All

    InfuSystem Announces CEO Transition; Carrie Lachance to Become Chief Executive Officer

    The Company Reaffirms Full Year 2025 Guidance: Revenue Growth of 8-10% and Adjusted EBITDA (non-GAAP) margin greater than 18.8% InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that Richard DiIorio will be stepping down as the Company's Chief Executive Officer, effective May 19, 2025. Concurrently, the Company announced that Carrie Lachance, the Company's President and Chief Operating Officer, and a member of the Company's board of directors, will assume the role of Chief Executive Officer effective May 19

    4/1/25 6:30:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem Appoints Ronald Hundzinski to the Board of Directors

    InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today the appointment of Ronald Hundzinski, as an independent director to InfuSystem's Board of Directors, effective November 12, 2024. Mr. Hundzinski will serve as a director until he stands for election at InfuSystem's next Annual Shareholders meeting in May 2025. Scott Shuda, Chairman of InfuSystem's Board of Directors, said, "We are pleased to welcome Ron to InfuSystem's Board. He adds both accounting and finance depth to our oversight and committee work and

    11/18/24 9:15:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem Appoints R. Rimmy Malhotra to the Board of Directors

    InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today the appointment of R. Rimmy Malhotra, a new independent director to InfuSystem's Board of Directors, effective September 20, 2022. Mr. Malhotra will serve as a director until he stands for election at InfuSystem's next Annual Shareholders meeting in May 2023. Scott Shuda, Chairman of InfuSystem's Board of Directors, said, "We are pleased to welcome Rimmy as a new independent director on InfuSystem's Board. Rimmy first invested in the Company in 2012, and has

    9/23/22 4:05:00 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care